Factors associated with sustained virological response in 24‐week telaprevir‐based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype

Abstract

In HCV genotype 1b patients with the minor IL28B SNP rs8099917 genotype, evaluating prior treatment response and achieving RVR and pretreatment serum fasting LDL-C concentrations were useful for predicting SVR achievement after 24-week telaprevir-based triple therapy.

Prediction of Sustained Virological Response to Telaprevir/Simeprevir-Based Triple Therapy in Patients with Genotype 1 Hepatitis C Virus Using Super-Early Viral Response within 2 Weeks

“…RVR has been found to be associated with SVR not only in the context of PEG-IFN/RBV therapy [16,17] but also with TVR/SMVbased triple therapy [10,13,[18][19][20]. The present study extracted both RVR and HCV RNA load at week 2 as predictive factors for SVR in univariate analysis, but only the latter was extracted in multivariate analysis.…”

“…In particular, rapid virological response (RVR), defined as undetectable serum HCV RNA at week 4, was associated with SVR after PEG-IFN/RBV therapy [16,17]. Similarly, RVR was associated with SVR after TVR/SMV-based triple therapy [10,13,[18][19][20]. However, there are few reports on predicting the occurrence of SVR earlier than week 4 after the initiation of protease inhibitor-based triple therapy [21][22][23].…”